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ABStRACt
Introduction: Multiple sclerosis (MS) is a chronic, inflammatory, (auto) immune disease of 
the central nervous system (CNS). Quality of life (QoL) refers to the perception of an individ-
ual’s life in the context of the system of culture and values in which they live. Aim: The aim of 
the study was to determine the distribution of cognitive disorders in people with MS. Methods: 
The prospective study included 135 participants with MS and 50 healthy participants. Partic-
ipants were divided into three groups: the first group consisted of 85 participants where the 
disease lasted longer than one year, the second group consisted of 50 participants with newly 
diagnosed MS, the third group consisted of 50 healthy participants. The instruments of clin-
ical assessment were: Extended Disability Score in Multiple Sclerosis Patients, Mini Mental 
Status, Beck Depression Scale, and Quality of Life Scale (SF-36, Contemporary Health Sur-
vey). Results: The quality of life related to health is impaired in the physical, mental dimension 
and overall quality of life. In the first group of participants, 62% had mild depression, and 
in the second group 38% of participants, while more severe forms were recorded in 16% of 
participants in both groups. As depression increases, the quality of life decreases in all mea-
sured dimensions, which would mean that depression negatively affects the quality of life. The 
results of all dimensions as well as the overall quality of life score are worse with the increase 
in the degree of clinical disability, for both groups of study patients. Conclusion: Quality of life 
is impaired in MS patients, and a higher degree of clinical disability and an increase in depres-
sive disorder are predictors of deteriorating quality of life in MS patients.
Keywords: Multiple sclerosis, quality of life, Depression.
1. INTRODUCTION
Multiple sclerosis (MS) is a chronic, inflammatory, (auto) immune dis-
ease of the central nervous system (CNS) whose etiological background is 
not completely clear (1). Etiologically, it represents the association of genetic 
predisposition and dysregulation in the immune system, with the influence of 
various risk factors from the environment (2). MS, the most common chron-
ic disabling disease of the CNS in young adults, affects 2.3 million people 
worldwide, is twice as common in women as in men, and usually occurs at a 
young age, or about 30 years. The course of MS is variable and unpredictable. 
According to the National Multiple Sclerosis Society, there are four types of 
MS: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), pri-
mary progressive MS (PPMS), and secondary progressive MS (SPMS). CIS 
is the first episode of neurological symptoms caused by inflammation and 
demyelination in the CNS, lasting at least 24 hours, and which does not meet 
the criteria for MS. RRMS is characterized by the appearance of defined sei-
zures (relapse or worsening) of new or increasing neurological symptoms, 
followed by periods of partial or complete recovery (remission). At the time 
of diagnosis, about 85% of patients had this type of MS. Eighty percent of 
patients with RRMS will eventually transition to a secondary progressive 
course (SPMS), with a gradual and progressive deterioration of neurological 
function (accumulation of disability) over time. If this progressive course oc-
curs from the onset of the disease, without early recurrence or remission, the 
patient develops PPMS, which accounts for 10% of patients (3). Symptoms 
most often (85-90%) occur in attacks (exacerbation or remission) or slowly 
progressively over time (4). Multiple sclerosis is characterized by a variety of 
symptoms that have a major impact on quality of life even in the early stages 
(5). In addition to individual motor, sensory, visual disturbances, brain stem 
and sphincter disturbances (6), which are expressed through the most widely 
used Kurtzke extended disability scale (EDSS score), there are other manifes-
ORIGINAL PAPER
doi: 10.5455/medarh.2020.74.368-373
MEd ARCh. 2020 OCt; 74(5): 368-373
RECEIVEd: AUG 26, 2020 | ACCEPtEd: OCt 13, 2020 
¹Clinic of Neurology, University Medical Center 
Tuzla, Tuzla, Bosnia and Herzegovina
²Faculty of Medicine, University of Tuzla, Tuzla, 
Bosnia and Herzegovina
³Center for Neurology, Health Center Tuzla, 
Tuzla, Bosnia and Herzegovina
 4Clinic of Neurology, Medical Center of 
University in Sarajevo, Sarajevo, Bosnia and 
Herzegovina
5Netherland Institute for Health Science, 
Erasmus Medical Center in Rotterdan, 
Rotterdam, Netrherlands
Corresponding author: Assistant Professor 
Aida Sehanovic, MD, PhD. Neuropsychiatrist. 
Clinic of Neurology, University Clinical Center 
Tuzla. Prof. Ibre Pasica 1, 75000 Tuzla, Bosnia 
and Herzegovina. Tel: ++ 387 61 721 171. 
E--mail: aida.sehanovic@gmail.com. ORCID iD: 
http//www.orcid.org/ 0000-0001-6192-2680.
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
© 2020  Aida Sehanovic, Suljo Kunic, Omer C. 
Ibrahimagic, dzevdet Smajlovic, Emir tupkovic,  
Admir Mehicevic, Emina Zoletic
Contributing Factors to the Quality of Life in Multiple Sclerosis
369ORIGINAL PAPER | MEd ARCh. 2020 OCt; 74(5): 368-373
Contemporary Health Survey (20). EDSS quantifies dis-
orders of certain functional systems (pyramidal system, 
cerebellum, brain stem, sensibility, intestines and blad-
der, visual system, cerebral functions and other func-
tions). Based on the state of the functional systems, the 
degree of disability is derived (0.0-normal neurological 
finding up to 10-death).
MMSE is used to assess the following cognitive func-
tions: orientation, repetition, computation, short-term 
memory, naming, reading, writing, executing complex 
commands, and copying. The total score is 30. Cogni-
tive functioning according to MMSE will be graded as 
normal if the score is 25-30. Beck’s scale for assessing 
depression is sensitive and specific that it can be used 
in making a diagnosis. The scale has 21 questions with 
four answer options graded from 0-3. An increase of 
almost above 10 speaks in favor of the presence of de-
pressive disorder. SF 36 is a short guide to health assess-
ment, consisting of 36 questions divided into eight ar-
eas (physical function, limitations of physical function, 
physical pain, social functioning, general mental health, 
emotional limitations, vitality and fatigue, general sense 
of health). It provides two general measures of function: 
physical component summary (PCS) and mental com-
ponent summary (MCS). Each question is scored from 1 
to 100, and results close to 100 indicate a better quality 
of life.
Participants from all three groups underwent basic 
testing and control testing for all groups of participants 
was performed one year after the primary testing. Statis-
tical processing was performed in SPSS ver. 13 or SPSS 
17.0 (Chicago, IL, USA).
4. RESULTS
Demographic and clinical characteristics of the par-
ticipants are shown in Table 1.
Participants of the first and second groups showed im-
paired quality of life in the physical, mental dimension 
and overall SF 36 score Table 2. 
Table 2 shows the distribution of all eight dimensions 
of quality of life for the first and second groups of par-
ticipants. It is noticed that in the second group of partic-
ipants the physical limitations were the least damaged. 
Participants of the first group show greater physical lim-
itations, vitality is worse and overall health. Both groups 
of participants have mental disorders, which are possi-
bly a consequence of coping with a serious illness and 
partly a consequence of the topographic distribution of 
demyelinating brain lesions.
Depression is an important predictor of the quali-
ty of life of people with MS. The degree of depression 
was measured using the Beck Depression Scale (BDS). 
Table 3 shows the prevalence of depression in the first 
and second groups of participants at initial testing and 
one year later. Chi square test revealed a statistically 
significant difference in the distribution of depression 
between the first and second group of participants due 
to the increased number of patients with mild / mod-
erate depression at initial testing and after one year (p 
<0.0001). We found that there is no statistically signif-
tations of MS that have a detrimental effect on overall 
functioning and quality of life, such as cognitive impair-
ment, depression, anxiety (7), fatigue, and pain (8).
WHO defines quality of life (QL) as the perception of 
an individual's life in the context of the culture and val-
ue system in which he or she lives, as well as in relation 
to their goals, expectations, standards and concerns. 
Some definitions of quality of life focus on the subjec-
tive perspective of the patient's health status (9, 10) 
while other constructions are broader and include ob-
jective indicators of health, housing and other material 
circumstances (11). Most researchers believe that both 
subjective and objective information are necessary to 
determine construction (12). Most QC models reflect a 
multidimensional conceptual approach, which often in-
cludes physical, mental, social, and functional aspects of 
health. Beyond these basic dimensions, many measures 
include disease- or treatment-specific variables (13). 
The combination of relapse, physical disability activity, 
and magnetic resonance imaging (MRI) activity reflects 
only part of the impact that MS has on a patient’s dai-
ly life. In recent decades, QoL measurements have also 
been considered increasingly important for assessing 
disease progression, response to treatment, and the lev-
el of care required by patients with MS (14). In fact, in 
recent years, re-searchers have recommended that the 
assessment of QoL be included in the definition of “No 
evidence of disease activity” (15).
2. AIM
The aim of the study was to determine the distribution 
of cognitive disorders in people with Multiple Sclerosis.
3. PATIENTS AND METHODS
The research was prospectively conducted at the Uni-
versity Clinical Center Tuzla, in the Clinic of Neurology 
for a period of 2.5 years. The sample included 135 partic-
ipants with MS and 50 healthy participants. Participants 
were divided into three groups: the first a) group con-
sisted of 85 patients with MS disease lasting more than 
one year, the second, b) group consisted of 50 patients 
diagnosed with newly diagnosed MS (disease lasting no 
longer than one year), the third, c) the group consisted 
of 50 healthy participants adapted to the experimental 
groups according to age, gender and education. The se-
lection of participants was done consecutively. Includ-
ing the criteria for the first and second group of partic-
ipants, the diagnosis of MS was made according to the 
valid McDonald criteria from 2011 (16). Including the 
criterion for the third group are participants who have 
no symptoms and signs of neurological diseases, nor 
cognitive disorders previously medically documented. 
Excluding criteria for the first and second groups are 
associated diseases and injuries of the brain and spinal 
cord. Demographic data (age, gender, level of education) 
were analyzed for each respondent who met the criteria 
for inclusion in the study.
The instruments of clinical assessment were: Extend-
ed Disability Status Scale (EDSS) (17); Mini Mental 
Status (MMSE) (18); Beck Depression Scale (19); SF 36 
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icant difference in the degree of depression of the first 
group of participants at initial testing and after one year 
(Chi square test, p = 0.12). We obtained the same results 
in the group of participants with newly diagnosed dis-
ease (second group), and there is no statistically signifi-
cant difference in the degree of depression after one year 
(Hi square test, p = 0.24).
Table 4 shows the significance of the differences in 
the correlation of the results of the SF-36 questionnaire 
with the BDS of the participants of the first, 
second and third groups of participants. All 
results have a negative correlation coeffi-
cient, which means that with the increase in 
the degree of depression, the quality of life of 
the participants decreases. The results of the 
physical and mental dimensions of quality of 
life as in the total SF-36 score are statistically 
significantly correlated with depression. As 
the degree of depression increases, the quality 
of life decreases in all measured dimensions 
(Spearman's rank correlation coefficient), 
which would mean that depression negatively 
affects the quality of life.
Table 5 shows the significance of differences 
in the correlation of SF 36 questionnaire re-
sults with EDSS participants with multiple sclerosis in 
the first group (with subgroups RRMS and SPMS) and 
the second group of participants.
All results have a negative correlation coefficient. The 
results of all dimensions as well as the overall quality of 
life score are statistically significantly correlated with the 
results of EDSS, for the group of newly discovered MS 
(second group) and for the group of old MS (first group). 
In the subgroup of the first group of participants, i.e. the 
RRMS group, we also found a statistically significant 
correlation of all dimensions of quality of life and EDSS, 
while in the subgroup SPMS there is no statistically sig-
nificant correlation between the results of individual di-
mensions and the overall quality of life score with EDSS 
Testing I Testing II
Control Group I Group II Control Group I Group II
Number of responders 50 85 50 50 80 45
RRMS  0 71 50 0 66 45
SPMS 0 14 0 0 14 0
Age in years 38 ± 5.8 42 ± 9.3 37.5 ±10.8 39 ± 5.8 43 ± 9.3 38.5 ±10.8
Gender (♀/♂) 35 / 15 60 / 25 41 / 9 35 / 15 59 / 21 39 / 6
Education in years 16 ± 1.8 12 ± 2.5 12 ± 2.4 16 ± 1.8 12 ± 2.5 12 ± 2.4
EDSS 0 2.5 ± 2.3 1.9 ± 1.8 0 3 ± 2.6 1.6 ± 1.5
Duration of disease in 
years 0 6 ± 4.0 < 1 0 7 ± 4.0 1
table 1. demographic and clinical characteristics of the participants. testing I - initial testing; testing II - testing after one year; Control - participants 
without multiple sclerosis; Group I - participants with multiple sclerosis which lasted more than one year; Group II - participants with newly 
diagnosed multiple sclerosis; RRMS - relapsing remitting form of multiple sclerosis; SPMS - secondary progressive form of multiple sclerosis; EdSS - 
extended scale of disability status in multiple sclerosis. A brief assessment of cognitive status via the minimum scale (MMSE) found that participants 
in the first and second groups had average scores that were in the reference values (the first group of subjects had an average value of MMSE 27, and 
the second group 26.
Group I (>  1 yar) Gropu II (< 1 yar)
Testing I Testing II Testing I Testing II




Physical function 56.9 54.9 70.1 74.2
Role-physical 47.9 50.3 50 57.2
Body pain 80 78.5 85 86.2
General health 54.6 52.9 57 58.0
Vitality 48.9 46.2 53 55.7
Social functioing 69.8 65.9 63 68.1
Role emotional 63.5 65.4 61 64.4
Mental health 68 68.5 65 68.8
Physical health 57.7 56.6 63 66.2
Mental health 60.9 59.8 60 62.9
Total score 61.2 60.3 63 66.5
table 2. distribution of all eight dimensions of quality of life for the first 
and second group of participants.
Group I (>  1 yar) Gropu II (< 1 yar)
Testing I Testing II Testing I Testing II







depression 32 (37,6%) 25 (31,0%) 23 (46,0%) 24 (53,0%)
Mild / 
Borderline 39 (46,0%) 35 (44,0%) 19 (38,0%) 13 (29,0%)
Moderate / 
Severe 14 (16,4%) 20 (25,0%) 8 (16,0%) 8 (18,0%)
table 3. distribution of depression in participants of the first and 






Rho     p... Rho     p... Rho     p...
SF 36
Physical health -0,7073   <0.0001 -0,7396   0,0035 -0,7856     0,0001
Mental health -0,8317   <0,0001 -0,6780   0,0095 -0,8259     0,0001
Total score -0,8142   <0,0001 -0,7473   0,0030 -0,8213     0,0001
table 4. Correlation of SF-36 questionnaire results with Beck depression Scale SF 
36 - General generic questionnaire for measuring quality of life (short form 36); BdS - 
Beck depression Scale; Rho - Spearman rank correlation coefficient; p- the possibility 
of a random difference of the bidirectionally tested hypothesis. Control group-healthy 
participants, First group of participants with disease duration longer than one year; An-
other group of participants with newly diagnosed MS. RRMS-relapsing-remitting form 
of the first group of participants; SPMS-secondary-progressive from of the first group 
of participants.
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results. This could be explained by the fact that the pro-
gression of the disease to one degree leads to adaptation 
to the disease and acceptance of disability.
5. DISCUSSION
Multiple sclerosis is a neurodegenerative progressive 
disorder that affects younger adults at the most produc-
tive age, women getting sick more often. In this study, 
women were more represented than men in both groups 
of participants (70.5% in the first group and 82% in the 
second group). The average age of the participants in 
the first group was 42.0 +/- 9.3 years, and in the sec-
ond group 37.5 +/- 10.8 years. This result correlates with 
the results in other studies (2, 21, 22). The control group 
(gender and age distribution) was adjusted to the demo-
graphic parameters of the first and second groups. In 
this study, we had 82% of subjects with relapsing-remit-
ting type and 18% of participants with secondary-pro-
gressive type of disease, in correlation with other studies 
(23).
Quality of life is a multidimensional concept that con-
nects physical, social, psychological and emotional func-
tioning. Quality of life in relation to health is defined by 
aspects that affect the patient's health status and is a 
measure of clinical assessment of quality of life, disease 
progression and the effects of therapy (6). Health assess-
ment based on patient responses through a 36-question 
questionnaire from the health profile (SF-36) was most 
used in medical studies. The SF-36 questionnaire simply 
highlights the areas of health affected by the disease, and 
can reveal how patients cope with the disease.
Depression can occur during MS, even in mild forms 
of the disease (24), and a higher risk of depression has 
been reported in the first years after diagnosis (25). Dis-
ease activity, but not its duration, has been associated 
with depression and anxiety (26). Studies suggest that 
there are neurobiological risk factors associated with 
MS that determine the increased incidence of depres-
sive disorders in these patients, such as increased le-
sion load in the left funiculus arcuatus (27), as well as 
in the prefrontal cortex, anterior temporal lobe, and pa-
rietal lobe (28). Cortical atrophy in regions located in 
bilateral frontal lobes, as well as parietal and occipital 
lobes, has been associated with depression 
in patients with MS (29). The hippocampus 
plays a key role in mood regulation. The 
study found true variations in hippocam-
pal shape in women with MS with depres-
sion and that these changes were associated 
with an impact on symptoms but not with 
vegetative symptoms of depression (30). 
Another study showed changes in the corti-
co-striatal-pallidothalamic loop in patients 
with MS with depression, namely progres-
sive loss of gray matter in the limbic basal 
ganglion structures, such as the globus pal-
lidus, and thalamus, which can lead to typ-
ical deficits in hedonic motivations; on the 
other hand, atrophy of the prefrontal cortex 
may contribute to maladaptive coping strat-
egies, promoting the development of depressive symp-
toms (31).
Participants in our study show a depressive disorder. 
In the first group, 62% of participants had mild depres-
sion, and in the second group 38% of participants, while 
more severe forms were recorded in 16% of participants 
in both groups. We found that the results of the physi-
cal and mental components of quality of life as well as 
the overall SF-36 scores were statistically significantly 
correlated with the results of the Beck Depression Scale. 
As the degree of depression increases, the quality of 
life decreases in all measured dimensions. Depression 
has been shown to be an important predictor of dete-
riorating quality of life in people with MS. This result is 
correlated with the results of Fuvesi et al. who find that 
depression as the statistically most significant factor is 
the weakened mental component of health and SF-36. 
Moreover, he also found that in depressed MS patients, 
QOL worsened to a significant extent (32). Similar re-
sults were found in the study by Salehpoor et al. (33) 
that depression alone is a significant predictor of men-
tal health disorders. Also, this finding is consistent with 
previous reports of MS patients (34, 35). Based on the 
interpretation of this finding, depression impairs the 
motivation, interest and cooperation of the patient; this 
in turn can affect vitality, social function, mental health, 
and the mental health dimension in general. Another in-
terpretation is that depression can distort people's views 
of the world and their health and change it in a way that 
worsens their self-esteem (36).
The results of all dimensions as well as the overall 
quality of life score are statistically significantly correlat-
ed with the degree of clinical disability (EDSS) for both 
groups of study participants. A nonlinear relationship 
between the degree of disability and quality of life was 
found in a study by Twork et al. (37). With the worsen-
ing of the state of disability, poorer physical and men-
tal health, worse score of all subscales, as well as poorer 
cognitive functions were recorded. However, while pa-
tients with EDSS between 4.5 and 6.5 differed signifi-
cantly compared to patients with a lower score (EDSS 
0-4.0), a smaller difference was observed between the 





Rho     p... Rho     p... Rho     p...
SF 36
Physical health -0,7064     <0.0001  0,1099     0,7043 -0,6724    <0,0001
Mental health -0,4113      0,0005 -0,2198     0,4448 0,4953     0,0003
Total score -0,6146     <0,0001 -0,1736     0,5526 -0,5783    <0,0001
table 5. Correlation of SF-36 questionnaire results with EdSS respondents of the first and 
second groups. SF 36 - General generic questionnaire for measuring quality of life (short 
form 36); EdSS - Expanded disability Status Scale; Rho - Spearman rank correlation 
coefficient; p.- the possibility of a random difference of the bidirectionally tested 
hypothesis. the first group of participants with a disease duration of more than one year; 
the second group of participants with newly diagnosed MS; RRMS-relapsing-remitting 
form of the first group of participants; SPMS-secondary-progressive froma of the first 
group of par-ticipants.
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group with EDSS 4.5-6.5 and the group with EDSS 7.0 
to 10). These results were similar for all dimensions of 
quality of life (physical, mental, and overall quality of 
life). In this study, a significant and negative associa-
tion between disability and quality of life was found. 
Thus, the results suggest that when mobility is impaired 
(without the use of a wheelchair) there is a more pro-
nounced impairment of quality of life, and the longer 
wheelchair-bound patients show no additional impair-
ment in most health-related domains of quality of life. 
Pfaffenberger illustrated that increased impairment in-
tensity and limited mobility are directly related to re-
duced quality of life in patients with MS (38). A study by 
Ghaem and Haghighi (39) also showed that MS patients 
have moderate to poor mental and physical health. The 
degree of clinical disability expressed by the EDSS re-
sult, as well as the severity of fatigue and the quality of 
sleep were significant indicators that correlated with 
the quality of physical and mental health. This study 
also showed that demographic data (age, gender, mar-
ital status, age of education) and disease duration had 
no impact on quality of life after conducting statistical 
modeling. As the quality of mental and physical health is 
in a high relationship with each other, patients with MS 
need special attention from health professionals and the 
assessment of those patients who may need additional 
psychological support (39).
6. CONCLUSION
The presence of depression worsens the quality of 
life of people with MS, impairs the mental and physical 
components of quality of life. A higher degree of disabil-
ity leads to a poorer quality of life of MS patients for the 
physical and mental component of health as the overall 
quality of life of the participants.
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